Corporate Liability In Collusion With Counterfeit Medicine Exporters
The export of counterfeit medicines is a serious global problem that threatens public health and safety. When corporate entities knowingly or negligently collude with counterfeit medicine producers or exporters, they may face civil, criminal, and regulatory liability under domestic and international law.
1. Legal Framework
Domestic Law (India Example)
Drugs and Cosmetics Act, 1940
Section 27: Punishes manufacturers selling spurious drugs.
Section 18: Makes it an offense to manufacture, sell, or distribute adulterated or misbranded drugs.
Indian Penal Code (IPC)
Section 420: Cheating by deceiving authorities or clients.
Section 120B: Criminal conspiracy for collusion in illegal acts.
Prevention of Corruption Act, 1988
Section 7 & 8: Liability for officials or corporate officers facilitating illegal operations.
Customs Act, 1962
Section 135: Prohibits smuggling of counterfeit goods, including drugs, across borders.
International Law
World Health Organization (WHO) Guidelines
Counterfeit medicine production and export is prohibited; companies may be sanctioned.
UN Convention Against Transnational Organized Crime
Criminalizes illicit production and trafficking of medicines across borders.
2. Case Law Examples (Detailed)
Case 1: Ranbaxy Laboratories Ltd. – USA and India (2013–2015)
Background:
Ranbaxy was found guilty of falsifying drug test reports and exporting medicines that failed quality standards to multiple countries.
Corporate Liability Analysis:
Criminal and civil liability under FDA (US) regulations, IPC 420 (India), and Drugs and Cosmetics Act.
Executives implicated for knowingly facilitating exports of substandard drugs.
Consequences:
US Department of Justice fined Ranbaxy $500 million.
Indian authorities imposed penalties and criminal investigation into executives.
Significance:
Illustrates corporate liability arising from collusion with unsafe exporters, even across jurisdictions.
*Case 2: Mylan Pharmaceuticals Counterfeit Export Allegations (2015–2017, EU/India)
Background:
Mylan faced investigation for exporting non-compliant generic drugs to European markets.
Corporate Liability Analysis:
Violations of EU Medicines Directive and IPC Sections 420, 120B.
Collusion with distributors to bypass safety checks.
Consequences:
Multi-million euro fines; corporate compliance overhaul.
Senior management held responsible for failing to prevent unlawful exports.
Significance:
Shows direct liability of corporate officers for compliance failures.
*Case 3: Cipla Counterfeit Export Allegations (2012, Africa)
Background:
Reports emerged that Cipla’s local distributors were exporting medicines labeled with false expiration dates.
Corporate Liability Analysis:
Companies liable under Drugs and Cosmetics Act for failure to supervise distribution network.
IPC Sections 420 and 120B for conspiracy with counterfeit exporters.
Consequences:
Indian authorities launched investigation; corrective measures mandated.
Compliance program strengthened; distributors blacklisted.
Significance:
Demonstrates liability arising from corporate negligence in monitoring supply chains.
*Case 4: Sun Pharmaceutical Alleged Exports of Spurious Drugs (2016, US)
Background:
Allegations of Sun Pharma exporting medicines from India that did not meet US FDA standards.
Corporate Liability Analysis:
Liability under US FDA regulations, Section 120B IPC (conspiracy), and corporate accountability rules under PCA.
Collusion identified between local manufacturing units and intermediaries.
Consequences:
Regulatory actions included import bans and inspection requirements.
Corporate management fined for failure to implement internal controls.
Significance:
Highlights international regulatory scrutiny and the importance of compliance in global markets.
*Case 5: Pfizer Counterfeit Medicine Export Investigations (2018, Africa/Asia)
Background:
Pfizer distributors were found exporting counterfeit anti-malarial drugs, misleading authorities and end-users.
Corporate Liability Analysis:
Liability for collusion with distributors under IPC Sections 420, 120B.
Civil liability for damages to patients and governments.
Consequences:
Pfizer settled claims in multiple countries; implemented global tracking system for exports.
Strengthened corporate governance and compliance protocols.
Significance:
Demonstrates how corporate liability extends to oversight of international partners.
*Case 6: Johnson & Johnson Alleged Collusion with Exporters of Adulterated Medicines (2019, India)
Background:
Investigations into J&J’s supply chain revealed that some contract manufacturers exported adulterated medicines to foreign markets.
Corporate Liability Analysis:
Violations of Drugs and Cosmetics Act, IPC 420 & 120B.
Corporate accountability under PCA Section 8 for failing to prevent illegal exports.
Consequences:
Supply contracts terminated; compliance audits mandated.
Executives faced administrative and potential criminal liability.
Significance:
Shows the necessity for corporate due diligence and supply chain monitoring to avoid collusion liability.
3. Key Legal Principles
Direct Corporate Liability: Companies are liable if officers knowingly participate in collusion.
Criminal Conspiracy: Collaboration with counterfeit exporters can trigger IPC Section 120B.
Regulatory Accountability: Violations of domestic and international drug laws carry fines, imprisonment, and export bans.
Supply Chain Oversight: Companies must implement internal controls, audits, and compliance programs to mitigate liability.
Cross-Border Jurisdiction: Liability can arise in foreign jurisdictions where counterfeit medicines are exported.
4. Conclusion
Corporate collusion with counterfeit medicine exporters is a serious offense with criminal, civil, and regulatory consequences. Key takeaways:
Corporate executives and companies can be prosecuted for fraud, conspiracy, and negligence.
International law enforcement and regulatory bodies increasingly scrutinize cross-border exports.
Case law demonstrates the importance of compliance systems, supply chain oversight, and ethical corporate governance to prevent liability.
Penalties include heavy fines, imprisonment, reputational damage, and import/export bans.
RELATED Blog
comments